background
acut
respiratori
ill
ari
mostli
viral
etiolog
caus
signific
morbid
mortal
point
care
pcr
pocpcr
promis
new
technolog
rapid
viru
identif
util
emerg
depart
ed
yet
defin
object
primarili
investig
valu
pocpcr
rapidli
identifi
rsv
influenza
set
ed
triag
addit
assess
whether
rapid
knowledg
accur
test
result
would
improv
patient
manag
prevent
nosocomi
transmiss
optim
prescript
antimicrobi
ari
studi
design
prospect
cohort
studi
consecut
ed
patient
ari
symptom
peak
flu
season
conduct
patient
nasopharyng
swab
collect
test
use
pocpcr
devic
physician
patient
blind
result
viru
posit
neg
group
compar
ed
patient
room
placement
antimicrobi
therapi
order
specif
sensit
calcul
use
laboratorypcr
gold
standard
result
particip
pocpcr
posit
influenza
rsv
influenza
b
nearli
viru
posit
patient
place
room
share
nonari
patient
antibiot
prescrib
viru
posit
patient
oseltamivirelig
patient
receiv
therapi
pocpcr
sensit
ci
specif
ci
conclus
rapid
pocpcr
influenza
rsv
ed
triag
excel
sensit
specif
potenti
improv
social
distanc
practic
better
triag
increas
appropri
prescript
antimicrobi
acut
respiratori
ill
ari
caus
signific
morbid
mortal
adult
pediatr
patient
especi
winter
month
common
ari
etiolog
viral
influenza
respiratori
syncyti
viru
rsv
account
case
everi
year
influenza
estim
caus
hospit
death
unit
state
death
global
addit
immun
earli
treatment
social
distanc
good
hygien
reduc
incid
sever
diseas
peak
ari
season
emerg
depart
ed
experi
increas
demand
one
studi
found
ed
visit
peak
period
fever
respiratori
infect
symptom
peak
influenza
circul
associ
reduc
ed
throughput
effici
increas
ed
length
stay
lo
greater
proport
patient
depart
see
physician
addit
influenza
patient
median
lo
five
time
greater
ambulatori
ed
patient
ed
lack
space
accommod
increas
standard
oper
procedur
requir
patient
remain
crowd
wait
room
patient
room
becom
avail
space
limit
overcrowd
facilit
nosocomi
infect
rapid
identif
respiratori
virus
crucial
prevent
nosocomi
transmiss
especi
given
immun
compromis
inher
vulner
natur
ed
patient
includ
young
elderli
patient
chronic
health
condit
despit
numer
attempt
syndrom
formula
distinguish
influenza
respiratori
ill
lack
sensit
requir
inform
clinic
decis
regard
patient
care
isol
gold
standard
viral
test
laboratori
polymeras
chain
reaction
pcr
despit
high
sensit
specif
test
turnaround
time
tat
long
facilit
clinic
decisionmak
recent
technolog
advanc
pointofcar
poc
test
rapid
antigen
test
provid
test
result
less
min
yet
exhibit
low
sensit
recent
pocpcr
prove
promis
technolog
exhibit
high
sensit
specif
compar
laboratorypcr
perform
bedsid
without
complex
machineri
laboratorytrain
personnel
physician
report
higher
satisfact
tat
poc
test
versu
laboratori
analys
rapid
pocpcr
also
reduc
hospit
admiss
improv
appropri
use
antimicrobi
clinic
hospit
patient
pediatr
set
pocpcr
decreas
ancillari
test
chest
xray
urin
analys
save
cost
especi
multipl
virus
test
simultan
pocpcr
util
ari
ed
yet
defin
primari
studi
aim
investig
valid
pocpcr
identifi
rsv
influenza
compar
laboratorypcr
explor
whether
pocpcr
potenti
improv
ed
triag
social
distanc
prevent
nosocomi
transmiss
reduc
lo
secondarili
studi
examin
potenti
pocpcr
improv
appropri
antimicrobi
treatment
ari
conduct
prospect
observ
cohort
studi
universityaffili
tertiari
care
hospit
ed
decemb
march
studi
previous
describ
realtim
electron
alert
identifi
potenti
particip
base
follow
trigger
complaint
fever
cough
rhinorrhea
sore
throat
pcr
swab
order
chart
record
temperatur
train
research
coordin
receiv
notif
also
screen
ed
track
board
elig
patient
day
week
pm
potenti
particip
elig
ari
symptom
measur
fever
home
ed
cough
sore
throat
rhinorrhea
durat
symptom
h
week
age
elig
arriv
ambul
alreadi
receiv
oseltamivir
current
ill
exclud
verifi
elig
coordin
gain
approv
triag
physician
approach
patient
consent
patient
requir
urgent
manag
thu
exclud
obtain
consent
triag
physician
collect
nasopharyng
swab
sampl
coordin
test
immedi
influenza
influenza
b
rsv
use
roch
coba
influenza
ab
nucleic
acid
test
use
coba
liat
system
clia
waiv
pcr
assay
team
use
one
system
locat
ed
accord
manufactur
instruct
durat
studi
result
avail
approxim
min
coordin
also
collect
patient
inform
includ
demograph
clinic
histori
current
ill
relev
past
medic
histori
use
standard
redcap
data
form
host
stanford
center
clinic
informat
physician
blind
pocpcr
result
triag
patient
place
one
three
room
type
privat
cohort
share
decis
base
current
room
avail
attend
physician
discret
cohort
room
defin
room
patient
respiratori
symptom
recommend
world
health
organ
method
limit
respiratori
diseas
transmiss
share
room
one
patient
placement
occur
regardless
symptom
diagnosi
conveni
subset
patient
also
nasopharyng
sampl
sent
laboratorypcr
analysi
cours
ed
treatment
order
treat
physician
outsid
studi
procedur
follow
laboratori
describ
rogan
et
al
briefli
ed
nasopharyng
swab
viral
test
sent
offsit
facil
batchprocess
analyz
respiratori
viru
panel
genmark
virus
influenza
b
rsv
parainfluenza
metapneumoviru
rhinoviru
adenoviru
coronaviru
tat
hr
analys
perform
sa
sa
institut
cari
nc
basic
descript
statist
use
character
popul
demograph
clinic
variabl
physician
order
oseltamivir
antibiot
compar
pocpcr
posit
neg
patient
use
parametr
test
sensit
specif
pocpcr
calcul
use
standard
formula
assum
laboratorypcr
gold
standard
local
institut
review
board
approv
obtain
prior
begin
studi
verbal
consent
obtain
particip
parent
consent
minor
assent
particip
year
age
consent
process
patient
inform
pocpcr
devic
fdaclear
approv
hospit
use
medic
decisionmak
therefor
rapid
test
result
would
neither
share
physician
impact
care
studi
period
consecut
patient
screen
elig
screen
elig
enrol
consent
enrol
nasopharyng
swab
pocpcr
test
fig
illustr
patient
enrol
among
particip
gender
proport
fair
femal
median
age
year
rang
hispan
white
asianpacif
island
half
receiv
season
flu
vaccin
approxim
particip
histori
smoke
addit
sampl
characterist
detail
tabl
particip
n
posit
pocpcr
influenza
n
preval
rsv
n
influenza
n
preval
influenza
b
n
median
age
particip
infect
influenza
year
rang
influenza
b
year
rang
similar
p
rsv
infect
younger
popul
year
rang
p
onequart
n
patient
receiv
season
flu
vaccin
pocpcr
influenza
posit
patient
also
receiv
laboratorypcr
panel
n
posit
virus
influenza
rsv
includ
two
coinfect
one
addit
virus
influenza
rsv
tabl
display
room
placement
type
tat
laboratorypcr
test
result
less
half
particip
place
privat
room
major
pocpcr
posit
patient
place
share
room
time
room
placement
vari
wide
tabl
sampl
incident
test
laboratorypcr
pocpcr
pocpcr
highli
sensit
ci
specif
ci
compar
laboratorypcr
panel
tabl
detail
oseltamivir
antibiot
order
physician
antibiot
order
n
patient
six
patient
pocpcr
posit
receiv
antibiot
four
immunocompromis
chest
xray
suggest
communityacquir
pneumonia
oseltamivir
order
patient
one
pocpcr
posit
influenza
b
influenza
posit
case
n
elig
receiv
oseltamivir
year
old
histori
pulmonari
cardiovascular
diseas
ill
durat
h
receiv
therapi
elig
determin
use
criteria
center
diseas
control
prevent
cdc
pocpcr
test
could
potenti
modifi
treatment
decis
improv
proper
util
antimicrobi
therapi
case
n
first
studi
evalu
util
rapid
pocpcr
ed
triag
peak
ari
season
addit
excel
sensit
specif
compar
hospitalbas
laboratori
test
result
suggest
pocpcr
could
drastic
improv
social
distanc
practic
curb
nosocomi
infect
measur
like
cohort
patient
pathogen
symptom
reduc
risk
nosocomi
infect
recommend
half
patient
test
viru
posit
influenza
rsv
nearli
viru
posit
patient
place
share
room
patient
ari
symptom
ed
bed
includ
isol
room
remain
room
share
patient
median
bed
select
process
record
per
patient
discret
triag
physician
per
level
acuiti
room
avail
share
room
increas
likelihood
nosocomi
infect
caus
sever
complic
increas
morbid
among
ed
popul
ed
nationwid
overburden
crowd
especi
peak
ari
season
rapid
viru
detect
could
improv
triag
decis
allow
effici
investig
treatment
disposit
patient
concord
previou
studi
result
indic
potenti
suboptim
prescript
antimicrobi
among
respiratori
ill
patient
oseltamivir
reduc
complic
decreas
symptom
durat
recommend
cdc
infecti
diseas
societi
america
idsa
howev
threefourth
elig
case
receiv
therapi
similar
underutil
previous
report
appropri
deliveri
oseltamivir
especi
import
outbreak
situat
limit
viru
transmiss
antivir
medic
administ
within
h
symptom
onset
yet
delay
patient
present
lack
reliabl
clinic
diagnosi
diagnost
low
sensit
long
tat
make
time
antivir
deliveri
difficult
similarli
studi
suggest
rapid
test
result
could
improv
patient
manag
prevent
unnecessari
antibiot
administr
case
antibiot
prescrib
clear
etiolog
determin
like
patient
viral
sourc
may
caus
reconsider
antibiot
therapi
antibiot
resist
loom
threat
public
health
taken
togeth
pocpcr
could
anoth
clinic
intervent
employ
improv
antimicrobi
stewardship
poc
test
util
measur
speed
reliabl
exampl
despit
speed
rapid
antigen
technolog
becom
clinic
relev
due
low
sensit
addit
provid
rapid
result
previou
studi
shown
pocpcr
high
sensit
specif
compar
laboratorypcr
although
subset
patient
receiv
pocpcr
laboratorypcr
small
n
posit
sampl
pocpcr
sensit
specif
report
consist
previou
studi
fals
posit
record
studi
laboratorypcr
posit
metapneumoviru
viru
pocpcr
test
importantli
three
case
also
laboratorypcr
posit
metapneumoviru
one
case
pcr
posit
metapneumoviru
coronaviru
appropri
pocpcr
neg
pocpcr
detect
twothird
virusposit
patient
influenza
rsv
preval
far
outweigh
virus
laboratorypcr
panel
given
concern
pandem
influenza
ed
overcrowd
especi
peak
respiratori
season
studi
highlight
need
better
risk
recognit
infect
control
measur
upon
patient
arriv
mitig
infect
transmiss
align
guidelin
strongli
recommend
rapidli
identifi
patient
ari
triag
use
face
mask
spatial
separ
ari
patient
nonari
patient
moder
recommend
cohort
patient
reduc
ari
transmiss
health
care
worker
patient
ed
lo
affect
proxim
factor
room
avail
distal
factor
number
ancillari
diagnost
test
test
result
tat
peak
influenza
season
hospit
laboratori
burden
decreas
outlier
tat
laboratori
test
decreas
ed
lo
although
current
studi
design
evalu
rapid
pocpcr
impact
ed
lo
prior
studi
suggest
ed
lo
reduct
min
pocpcr
perform
postroom
ed
evalu
potenti
reduct
pocpcr
perform
triag
addit
clinic
impact
includ
reduc
ancillari
diagnost
test
cost
futur
studi
need
ascertain
decreas
ed
lo
may
reduc
diseas
transmiss
limit
contact
time
assess
pocpcr
costeffect
triag
peak
nonpeak
ari
season
prospect
cohort
studi
cdcdefin
ari
criteria
studi
enrol
hour
purpos
chosen
peak
ed
hour
examin
pocpcr
util
effici
manner
possibl
patient
offstudi
hour
declin
enrol
differ
particip
larg
number
patient
refus
particip
test
result
use
guid
care
howev
found
differ
demograph
screen
clinic
characterist
among
particip
nonparticip
addit
sampl
median
age
year
given
children
shed
higher
viru
titer
adult
report
pocpcr
sensit
could
fals
inflat
pocpcr
util
costeffect
also
examin
time
ed
burden
viral
respiratori
ill
util
may
reduc
studi
generaliz
potenti
handicap
conduct
singl
academ
medic
center
oper
protocol
diseas
burden
vari
geograph
hospit
type
howev
given
ari
burden
winter
month
propos
result
like
generaliz
peak
ari
season
ari
caus
signific
morbid
mortal
global
need
improv
diagnost
method
clear
data
suggest
peak
ari
season
rapid
accur
pocpcr
ed
triag
could
improv
social
distanc
measur
patient
present
ari
symptom
optim
antivir
antibiot
prescript
practic
shorten
patient
disposit
investig
ed
triag
pocpcr
util
nonpeak
ari
season
conduct
roch
molecular
system
inc
provid
sy
jvq
support
studi
coordin
investig
time
investig
initi
request
propos
roch
molecular
system
contribut
data
collect
data
analysi
write
manuscript
stanford
univers
institut
review
board
approv
obtain
prior
begin
studi
inform
consent
assent
document
english
spanish
approv
studi
waiver
document
signatur
document
consent
requir
particip
provid
appropri
consent
document
consent
obtain
everi
particip
studi
prior
enrol
particip
age
parent
consent
possibl
child
assent
obtain
